AVBPNasdaqPharmaceutical PreparationsFiscal year ends December 31
ArriVent BioPharma, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$17.94+1.28 (+7.68%)
Close on Oct 19, 2026
- Market cap
- $854.07M
- P/E (TTM)
- –
- Dividend yield
- –
SEC filings
40 of ArriVent BioPharma's most recent filings on SEC EDGAR
| Document | Form | Period | Filed | Source |
|---|---|---|---|---|
| Current report | 8-K | Oct 19, 2026 | Oct 19, 2026 | SEC EDGAR |
| Current report | 8-K | Oct 12, 2026 | Oct 13, 2026 | SEC EDGAR |
| Current report | 8-K | Oct 6, 2026 | Oct 6, 2026 | SEC EDGAR |
| Quarterly report | 10-Q | Jun 30, 2026 | Aug 12, 2026 | SEC EDGAR |
| Current report | 8-K | Aug 11, 2026 | Aug 12, 2026 | SEC EDGAR |
| Current report | 8-K | Jun 18, 2026 | Jun 22, 2026 | SEC EDGAR |
| Current report | 8-K | May 11, 2026 | May 11, 2026 | SEC EDGAR |
| Quarterly report | 10-Q | Mar 31, 2026 | May 11, 2026 | SEC EDGAR |
| Current report | 8-K | May 11, 2026 | May 11, 2026 | SEC EDGAR |
| Proxy statement | DEF 14A | Jun 18, 2026 | Apr 28, 2026 | SEC EDGAR |
| Current report | 8-K | Mar 17, 2026 | Mar 17, 2026 | SEC EDGAR |
| Annual report | 10-K | Dec 31, 2025 | Mar 5, 2026 | SEC EDGAR |
| Current report | 8-K | Mar 5, 2026 | Mar 5, 2026 | SEC EDGAR |
| Quarterly report | 10-Q | Sep 30, 2025 | Nov 10, 2025 | SEC EDGAR |
| Current report | 8-K | Nov 10, 2025 | Nov 10, 2025 | SEC EDGAR |
| Current report | 8-K | Sep 9, 2025 | Sep 9, 2025 | SEC EDGAR |
| Quarterly report | 10-Q | Jun 30, 2025 | Aug 11, 2025 | SEC EDGAR |
| Current report | 8-K | Aug 11, 2025 | Aug 11, 2025 | SEC EDGAR |
| Current report | 8-K | Jul 21, 2025 | Jul 21, 2025 | SEC EDGAR |
| Current report | 8-K | Jul 1, 2025 | Jul 2, 2025 | SEC EDGAR |
| Current report | 8-K | Jun 23, 2025 | Jun 23, 2025 | SEC EDGAR |
| Current report | 8-K | Jun 18, 2025 | Jun 20, 2025 | SEC EDGAR |
| Quarterly report | 10-Q | Mar 31, 2025 | May 12, 2025 | SEC EDGAR |
| Current report | 8-K | May 12, 2025 | May 12, 2025 | SEC EDGAR |
| Proxy statement | DEF 14A | Jun 18, 2025 | Apr 28, 2025 | SEC EDGAR |
| Current report | 8-K | Apr 23, 2025 | Apr 28, 2025 | SEC EDGAR |
| Current report | 8-K | Mar 11, 2025 | Mar 13, 2025 | SEC EDGAR |
| Current report | 8-K | Mar 3, 2025 | Mar 3, 2025 | SEC EDGAR |
| Annual report | 10-K | Dec 31, 2024 | Mar 3, 2025 | SEC EDGAR |
| Current report | 8-K | Jan 21, 2025 | Jan 22, 2025 | SEC EDGAR |
| Quarterly report | 10-Q | Sep 30, 2024 | Nov 14, 2024 | SEC EDGAR |
| Current report | 8-K | Nov 14, 2024 | Nov 14, 2024 | SEC EDGAR |
| Current report | 8-K | Sep 9, 2024 | Sep 9, 2024 | SEC EDGAR |
| Quarterly report | 10-Q | Jun 30, 2024 | Aug 14, 2024 | SEC EDGAR |
| Current report | 8-K | Aug 14, 2024 | Aug 14, 2024 | SEC EDGAR |
| Current report | 8-K | Jun 4, 2024 | Jun 5, 2024 | SEC EDGAR |
| Current report | 8-K | May 16, 2024 | May 16, 2024 | SEC EDGAR |
| Quarterly report | 10-Q | Mar 31, 2024 | May 8, 2024 | SEC EDGAR |
| Current report | 8-K | May 8, 2024 | May 8, 2024 | SEC EDGAR |
| Current report | 8-K | Apr 20, 2024 | Apr 22, 2024 | SEC EDGAR |